RxDoctor Payments Data

Maurice Sheetz

Pulmonary Disease · Vineland, NJNPI 1902832157

Payments from drug & device makers

$9,619in general payments, 2019–2025

Across 646 payments — averaging $14.89 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$908
  • Amgen$777
  • Philips North America LLC$604
  • Sanofi$539
  • Mylan Specialty L.p.$459
  • Advanced Respiratory, Inc$396
  • plus $6K from 52 others

What the payments were for

  • Food & beverage$9,586100%
  • Education$320%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$9,619 in reported general payments places this provider in the 80th percentile of 472 pulmonary disease providers in New Jersey.

See all pulmonary disease providers in New Jersey

Medicare billing

Part B allowed, 2024
$81,602
Medicare patients
295
Services billed
680

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
GlassiaAlpha-1-Proteinase Inhibitor14$147,301
OzempicSemaglutide37$73,869
JardianceEmpagliflozin61$65,032
Trelegy ElliptaFluticasone/Umeclidin/Vilanter67$62,052
Zileuton ErZileuton25$45,957
TrulicityDulaglutide25$31,203
EliquisApixaban59$30,950
JanuviaSitagliptin Phosphate38$24,621
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr26$22,726
XareltoRivaroxaban29$21,975
Combivent RespimatIpratropium/Albuterol Sulfate27$21,843
LinzessLinaclotide13$18,980
FarxigaDapagliflozin Propanediol16$17,130
Breztri AerosphereBudesonide/Glycopyr/Formoterol19$10,796
Atorvastatin Calcium651$9,668

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Takeda Pharmaceuticals U.S.A., Inc.Glassia$86$147,30114 claims
GSKTrelegy Ellipta, Anoro Ellipta, Arnuity Ellipta$371$88,900106 claims
Boehringer IngelheimJardiance, Combivent Respimat$241$86,87588 claims
Novo NordiskOzempic$360$73,86937 claims
AstraZenecaFarxiga, Breztri Aerosphere, Symbicort, Bevespi Aerosphere$908$41,59671 claims
Lilly USA, LLCTrulicity$268$31,20325 claims
PfizerEliquis$269$30,95059 claims
MerckJanuvia$180$24,62138 claims
Johnson & JohnsonXarelto$142$21,97529 claims
AbbVieLinzess, Synthroid$220$20,83033 claims
Almatica Pharma LLCSertraline Hcl$15$2,27281 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 472 pulmonary disease providers in New Jersey.

Other pulmonary disease in Vineland

See the full list for New Jersey

Where these figures come from

Is this you, or does something look wrong? →